Literature DB >> 10810000

The risk of ipsilateral versus contralateral recurrent deep vein thrombosis in the leg. The DURAC Trial Study Group.

P Lindmarker1, S Schulman.   

Abstract

OBJECTIVES: To investigate the risk of ipsilateral versus contralateral recurrent deep vein thrombosis in the leg.
DESIGN: An open prospective long term follow-up multicentre trial. Patients were followed by frequent outpatient visits at each centre during the first 12 months after inclusion and thereafter annually.
SETTING: Sixteen hospitals in central Sweden.
SUBJECTS: A total of 790 consecutive patients with objectively verified first episode of acute deep vein thrombosis and without diagnosed malignant disease were recruited from a randomized study comparing 6 weeks with 6 months of oral antivitamin K therapy as secondary thromboprophylaxis. MAIN OUTCOME MEASURES: Deep vein thrombosis in the contralateral leg was confirmed by venography or ultrasound. With regard to the ipsilateral leg, venography was required.
RESULTS: A recurrent episode of venous thromboembolism was documented in 192 patients after a mean (+/-SD) period of 31(+/-29) months. In 26 additional patients with ipsilateral symptoms the diagnostic critera were not fulfilled. One hundred and eleven patients have deceased and 69 patients withdrew from the study. The 392 patients without recurrent episodes were followed for a median of 96 months with 90% for at least 48 months. An objectively verified recurrent contralateral and ipsilateral deep vein thrombosis occurred in 95 and 54 cases, respectively, and in 41 patients pulmonary embolism was documented. In two patients thromboses with unusual locations were registered. The risk of contralateral versus ipsilateral recurrence was significantly increased with a risk ratio of 1.6 (95% confidence interval 1.4-1.9) in a time to event model. In a multivariate analysis none of the investigated variables were significantly associated with the side of recurrent thrombosis.
CONCLUSIONS: The risk of a recurrent deep vein thrombosis is increased in the contralateral leg. This brings into question the importance of an impaired venous flow for recurrent episodes of thrombosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10810000     DOI: 10.1046/j.1365-2796.2000.00662.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  6 in total

Review 1.  Duration of anticoagulation for venous thromboembolism.

Authors:  C Kearon
Journal:  J Thromb Thrombolysis       Date:  2001-09       Impact factor: 2.300

2.  Predictive Value of Mean Platelet Volume for Pulmonary Embolism Recurrence.

Authors:  Omer Araz; Fadime Sultan Albez; Elif Yilmazel Ucar; Bugra Kerget; Nafiye Yılmaz; Metin Akgun
Journal:  Lung       Date:  2017-06-15       Impact factor: 2.584

3.  Value of platelet indices in identifying complete resolution of thrombus in deep venous thrombosis patients.

Authors:  Utkan Sevuk; Rojhat Altindag; Mehmet Veysi Bahadir; Nurettin Ay; Ertan Demirtas; Fırat Ayaz
Journal:  Indian J Hematol Blood Transfus       Date:  2014-04-02       Impact factor: 0.900

4.  An Intact Dissecting Baker's Cyst Mimicking Recurrent Deep Vein Thrombosis.

Authors:  Sarah Jamshed; L Michael Snyder
Journal:  J Investig Med High Impact Case Rep       Date:  2016-05-13

Review 5.  Recurrent venous thromboembolism: what is the risk and how to prevent it.

Authors:  Gualtiero Palareti
Journal:  Scientifica (Cairo)       Date:  2012-09-17

Review 6.  Diagnosis and Treatment of Lower Extremity Deep Vein Thrombosis: Korean Practice Guidelines.

Authors:  Seung-Kee Min; Young Hwan Kim; Jin Hyun Joh; Jin Mo Kang; Ui Jun Park; Hyung-Kee Kim; Jeong-Hwan Chang; Sang Jun Park; Jang Yong Kim; Jae Ik Bae; Sun Young Choi; Chang Won Kim; Sung Il Park; Nam Yeol Yim; Yong Sun Jeon; Hyun-Ki Yoon; Ki Hyuk Park
Journal:  Vasc Specialist Int       Date:  2016-09-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.